TY - JOUR
T1 - Noninvasive Diagnosis and Evaluation of Curative Surgery for Gastric Cancer by Using NMR-based Metabolomic Profiling
AU - Jung, Jeeyoun
AU - Jung, Youngae
AU - Bang, Eun Jung
AU - Cho, Sung il
AU - Jang, You Jin
AU - Kwak, Jung Myun
AU - Ryu, Do Hyun
AU - Park, Sungsoo
AU - Hwang, Geum Sook
N1 - Funding Information:
ACKNOWLEDGMENT This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning, Korea (2010-0024825, NRF-2010-0019394, 2013M3A9B6046418, and Creative Allied Project (CAP)), the Korea Institute of Oriental Medicine (K14281), and the Korea Basic Science Institute (T33409).
Publisher Copyright:
© 2014, Society of Surgical Oncology.
PY - 2014
Y1 - 2014
N2 - Methods: A total of 154 urine samples from GC patients and healthy individuals and 30 pairs of matched tumor and normal stomach tissues were collected. Multivariate analysis was performed on urinary and tissue metabolic profiles acquired using 1H nuclear magnetic resonance and 1H high-resolution magic angle spinning spectroscopy, respectively. In addition, metabolic profiling of urine from GC patients after curative surgery was performed.Background: Mass screening for gastric cancer (GC), particularly using endoscopy, may not be the most practical approach as a result of its high cost, lack of acceptance, and poor availability. Thus, novel markers that can be used in cost-effective diagnosis and noninvasive screening for GC are needed.Results: Multivariate statistical analysis showed significant separation in the urinary and tissue data of GC patients and healthy individuals. The metabolites altered in the urine of GC patients were related to amino acid and lipid metabolism, consistent with changes in GC tissue. In the external validation, the presence of GC (early or advanced) from the urine model was predicted with high accuracy, which showed much higher sensitivity than carbohydrate antigen 19-9 and carcinoembryonic antigen. Furthermore, 4-hydroxyphenylacetate, alanine, phenylacetylglycine, mannitol, glycolate, and arginine levels were significantly correlated with cancer T stage and, together with hypoxanthine level, showed a recovery tendency toward healthy controls in the postoperative samples compared to the preoperative samples.Conclusions: An urinary metabolomics approach may be useful for the effective diagnosis of GC.
AB - Methods: A total of 154 urine samples from GC patients and healthy individuals and 30 pairs of matched tumor and normal stomach tissues were collected. Multivariate analysis was performed on urinary and tissue metabolic profiles acquired using 1H nuclear magnetic resonance and 1H high-resolution magic angle spinning spectroscopy, respectively. In addition, metabolic profiling of urine from GC patients after curative surgery was performed.Background: Mass screening for gastric cancer (GC), particularly using endoscopy, may not be the most practical approach as a result of its high cost, lack of acceptance, and poor availability. Thus, novel markers that can be used in cost-effective diagnosis and noninvasive screening for GC are needed.Results: Multivariate statistical analysis showed significant separation in the urinary and tissue data of GC patients and healthy individuals. The metabolites altered in the urine of GC patients were related to amino acid and lipid metabolism, consistent with changes in GC tissue. In the external validation, the presence of GC (early or advanced) from the urine model was predicted with high accuracy, which showed much higher sensitivity than carbohydrate antigen 19-9 and carcinoembryonic antigen. Furthermore, 4-hydroxyphenylacetate, alanine, phenylacetylglycine, mannitol, glycolate, and arginine levels were significantly correlated with cancer T stage and, together with hypoxanthine level, showed a recovery tendency toward healthy controls in the postoperative samples compared to the preoperative samples.Conclusions: An urinary metabolomics approach may be useful for the effective diagnosis of GC.
UR - http://www.scopus.com/inward/record.url?scp=84939872110&partnerID=8YFLogxK
U2 - 10.1245/s10434-014-3886-0
DO - 10.1245/s10434-014-3886-0
M3 - Article
C2 - 25092158
AN - SCOPUS:84939872110
SN - 1068-9265
VL - 21
SP - 736
EP - 742
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 4
ER -
